Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years.
The big biotech's stock is up more than 40% so far in 2017 -- the best performance of any biotech or pharma company with a market cap above $50 billion. Those gains can be traced to a string of positive developments for AbbVie, the most important of which happened in the last couple of months. Given everything that's going right for AbbVie, is it the best biotech stock to buy right now?
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Aktie
Die Merck & Co. Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Ein Kursziel von 125 € für Merck & Co. Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 106.4 €.